Jobs
-
Prosonix has submitted an MAA for its PSX1001 fluticasone propionate MDI for the treatment of asthma, triggering a milestone payment from Mylan, the company has announced. In April 2014, Mylan acquired marketing rights for PSX1001… Read more . . .
-
3M Drug Delivery Systems is marking the 25th anniversary of the launch of the Aerolin Autohaler breath-activated salbutamol (albuterol) MDI. According to the company, over 120 million units of the Autohaler device have been manufactured… Read more . . .
-
Contract development company MedPharm has announced a new fast track service for topical formulation development, including for respiratory delivery. The company offers development services for a variety of OINDP formulations, including MDIs, DPIs, inhalation solutions,… Read more . . .
-
According to the FDA, the agency has issued a tentative approval of an application by PulmoFlow, Inc. to market tobramycin 300 mg/5 ml inhalation solution. PulmoFlow, Inc. was established in Virginia in 2013. The company’s… Read more . . .
-
Main purpose of the job You will take responsibility for, and participate in, the complete development cycle for Medical Product development, from preparing specifications and architecture design through to approval for volume production. The position… Read more . . .
-
Civitas Therapeutics has announced that all of its existing investors, plus seven new investors, participated in a $55 million Series C financing round. The company is developing products based on respiratory delivery technology acquired from… Read more . . .
-
The Medicon Valley Inhalation Consortium (MVIC) has announced that Ola Nerbrink has succeeded Orest Lastow as CEO. Nerbrink was previously MVIC’s VP of Business Development. Lastow, who founded MVIC in 2012, left the position in… Read more . . .
-
Molins Technologies has announced the addition of the disk format µ-check to their µ-check line of check weighers. The standard µ-check can weigh individual DPI blisters alone or in blister strips. The new µ-check machine… Read more . . .
-
Sandoz has announced that the Mexican health authority, COFEPRIS, has approved the company’s marketing application for the Airflusal Forspiro salmeterol/fluticasone DPI for the treatment of asthma and for COPD. Three dosage levels were approved: 50-100… Read more . . .
-
GlaxoSmithKline has announced that it has received FDA approval for its fluticasone furoate DPI, to be marketed as Arnuity Ellipta, for the maintenance treatment of asthma. The approval is for 100mcg and 200mcg doses and… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA